|Table of Contents|

Expressions and clinical significances of PVT1 and miR-195 in papillary thyroid carcinoma

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2020 04
Page:
582-586
Research Field:
Publishing date:

Info

Title:
Expressions and clinical significances of PVT1 and miR-195 in papillary thyroid carcinoma
Author(s):
Li Yongfeng; Wang Xiaoqing; Wang Huihui; Chen Guoliang; Zhang Hui
Department of Endocrinology,First Affiliated Hospital of Henan University of Technology (Jiaozuo Second People's Hospital),Henan Jiaozuo 454000,China.
Keywords:
papillary thyroid carcinoma; PVT1; miR-195; correlation; clinicopathological parameters
PACS:
R736.1
DOI:
10.3969/j.issn.1672-4992.2020.04.013
Abstract:
Objective：To investigate the expressions and clinical significances of long non-coding RNA plasmacytoma variant translocation 1 (lncRNA PVT1) and miR-195 in thyroid papillary carcinoma (PTC) tissues.Methods:120 patients with PTC admitted to the department of endocrinology and thyroid surgery of our hospital from January 2017 to December 2018 were selected for the study (PTC group),120 patients with benign thyroid lesions as the benign lesion group,and normal thyroid tissues beyond 4 cm adjacent to cancer as the control group.Quantitative fluorescence PCR (qRT-PCR) was used to detect the levels of PVT1 and miR-195 in tissues,and their relationships with clinicopathological parameters.The correlation between the two expressions and their diagnostic values of PTC were analyzed.Results:The level of PVT1 in cancer tissues of PTC group was higher than that of benign lesion group and control group (P＜0.05),there was no significant difference between benign lesion group and control group (P＞0.05),there were significant differences among the three groups (P＜0.05).The level of miR-195 in cancer tissues of PTC group was lower than that of benign lesion group and control group (P＜0.05).The benign lesion group was lower than the control group (P＜0.05).There were significant differences among the three groups (P＜0.05).The expression levels of PVT1 and miR-195 were not correlated with gender,age,and tumor size (P＞0.05),but with TNM stage and lymph node metastasis (P＜0.05).Pearson correlation analysis showed that the expressions of PVT1 and miR-195 were negatively correlated in PTC patients (r=-0.840,P=0.000).ROC curve showed that the AUC of PVT1 was 0.769，the sensitivity was 60.00%,and the specificity was 90.00%，the AUC of miR-195 was 0.892,the sensitivity was 81.67%,and the specificity was 83.33%.Conclusion:The expression of PVT1 is high and the expression of miR-195 is low in PTC patients.They are negatively correlated,and related to TNM and lymph node metastasis.It has high diagnostic value and may be involved in the occurrence and development of PTC.

References:

［1］ Faquin WC,Wong LQ,Afrogheh AH,et al.Impact of reclassifying noninvasive follicular variant of papillary thyroid carcinoma on the risk of malignancy in The bethesda system for reporting thyroid cytopathology［J］.Cancer Cytopathology,2016,124(3):181-187.
［2］ Thompson LD.Ninety-four cases of encapsulated follicular variant of papillary thyroid carcinoma:A name change to noninvasive follicular thyroid neoplasm with papillary-like nuclear features would help prevent overtreatment［J］.Mod Pathol,2016,29(7):698-707.
［3］ ZHANG ZQ,Xu TW,WANG CX.PVT1 in the diagnosis,development,prognosis and drug resistance of tumors［J］.Modern Oncology,2018,26(7):1138-1144.［张子秋,徐天蔚,王朝霞.PVT1在肿瘤诊断、发生发展、预后和耐药中的研究进展［J］.现代肿瘤医学,2018,26(7):1138-1144.］
［4］QIN Qingqing,LI Tingting,ZHENG Yongqin,et al.Research progress on the mechanism of microRNA in papillary thyroid carcinoma［J］.Basic & Clinical Medicine,2017,37(8):1184-1189.［秦青青,李婷婷,郑永钦,等.microRNA在甲状腺乳头状癌中作用机制的研究进展［J］.基础医学与临床,2017,37(8):1184-1189.］
［5］ Zhou Q,Chen F,Zhao J,et al.Long non-coding RNA PVT1 promotes osteosarcoma development by acting as a molecular sponge to regulate miR-195［J］.Oncotarget,2016,7(50):82620-82633.
［6］ ZHANG S,JIANG XH.Analysis of risk factors associated with thyroid papillary carcinoma in younger age groups［J］.Journal of Clinical Otorhinolaryngology Head and Neck Surgery,2018,28(8):606-609.［张帅,蒋孝会.低龄型不同年龄段甲状腺乳头状癌患者相关危险因素分析［J］.临床耳鼻咽喉头颈外科杂志,2018,28(8):606-609.］
［7］ ZHOU B,TIAN W,ZANG Y.Efficacy of different treatments for patients with papillary thyroid cancer:A comparative study［J］.Academic Journal of Chinese Pla Medical School,2016,37(7):739-741.［周彬,田文,臧宇.甲状腺乳头状癌不同治疗方式的疗效比较［J］.解放军医学院学报,2016,37(7):739-741.］
［8］ LI W,CHNE XM,WU G.Roles of long non-coding RNA in papillary thyroid carcinoma［J］.International Journal of Endocrinology and Metabolism,2015,35(6):413-416.［李潍,陈晓铭,武革.长链非编码RNA在甲状腺乳头状癌中的作用［J］.国际内分泌代谢杂志,2015,35(6):413-416.］
［9］ DING J,LI D,GONG MZ,et al.Expression and clinical significance of the long non-coding RNA PVT1 in human gastric cancer［J］.OncoTargets and Therapy,2015,35(6):1615-1617.［丁健,李丹,龚敏贞,等.长链非编码RNA-PVT1在人胃癌组织中的表达及临床意义［J］.中国老年学杂志,2015,35(6):1615-1617.］
［10］ WENG X,HONG XM.Expression of lincRNA-PVT1 in thyroid carcinoma and its clinicopathological significance［J］.Journal of Practical Oncology,2017,32(1):57-61.［翁侠,洪晓明.LincRNA-PVT1在甲状腺癌组织中的表达及意义［J］.实用肿瘤杂志,2017,32(1):57-61.］
［11］ Zhang X,Tao T,Liu C,et al.Downregulation of miR-195 promotes prostate cancer progression by targeting HMGA1［J］.Oncology Reports,2016,36(1):376-382.
［12］ Zhen L,Hua W,Wang Z,et al.MiR-195 inhibits the proliferation of human cervical cancer cells by directly targeting cyclin D1［J］.Tumor Biology,2016,37(5):6457-6463.
［13］ Cui D,Yu CH,Liu M,et al.Long non-coding RNA PVT1 as a novel biomarker for diagnosis and prognosis of non-small cell lung cancer［J］.Tumor Biology,2016,37(3):4127-4134.
［14］ Yin Y,Hong S,Yu S,et al.MiR-195 inhibits tumor growth and metastasis in papillary thyroid carcinoma cell lines by targeting CCND1 and FGF2［J］.Int J Endocrinol,2017,42(9):6180425-6180428.
［15］ Zhou Q,Chen J,Feng J,et al.Long noncoding RNA PVT1 modulates thyroid cancer cell proliferation by recruiting EZH2 and regulating thyroid-stimulating hormone receptor (TSHR)［J］.Tumor Biology,2016,37(3):3105-3113.
［16］ Jian Z,Ye Q,Li C,et al.Upregulation of miR-195 enhances the radiosensitivity of breast cancer cells through the inhibition of BCL-2［J］.International Journal of Pharmaceutics,2017,523(1):300-309.
［17］ Wu D,Li Y,Zhang H,et al.Knockdown of lncRNA PVT1 enhances radiosensitivity in non-small cell lung cancer by sponging miR-195.［J］.Cellular Physiology & Biochemistry,2017,42(6):2453-2466.
［18］ Shen CJ,Cheng YM,Wang CL.LncRNA PVT1 epigenetically silences miR-195 and modulates EMT and chemoresistance in cervical cancer cells［J］.Journal of Drug Targeting,2017,25(7):637-644.

Memo

Memo:
河南理工大学基本科研业务费专项项目(编号：NSFRF170708)
Last Update: 2019-12-26